Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer

EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB

(2015) Kailong Lin et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Cancer statistics, 2015

(2015) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

CommonEGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors

(2015) Noemi Reguart et al.   Future Oncology

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

(2015) Scott N. Gettinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Non–Small Cell Lung Cancer, Version 6.2015

(2015) David S. Ettinger et al.   Journal of the National Comprehensive Cancer Network

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

(2015) Nan Chen et al.   Journal of Thoracic Oncology

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

(2015) Jeffrey S Weber et al.   LANCET ONCOLOGY

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs

(2015) Yanna Tang et al.   Oncotarget

Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma

(2015) Weiqing Jing et al.   Journal for ImmunoTherapy of Cancer

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer

(2014) K. Azuma et al.   ANNALS OF ONCOLOGY

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients

(2014) A D'Incecco et al.   BRITISH JOURNAL OF CANCER

Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients

(2014) Tanusree Paul et al.   EUROPEAN JOURNAL OF CANCER

Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes

(2014) Naoko Okiyama et al.   JOURNAL OF AUTOIMMUNITY

The effect of resveratrol and its methylthio-derivatives on EGFR and Stat3 activation in human HaCaT and A431 cells

(2014) Michal Cichocki et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy

(2013) T Kumai et al.   BRITISH JOURNAL OF CANCER

Dosing to rash: A phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503)

(2013) J.R. Brahmer et al.   EUROPEAN JOURNAL OF CANCER

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

(2013) E. A. Akbay et al.   Cancer Discovery

Combination immunotherapy approaches

(2012) C. G. Drake   ANNALS OF ONCOLOGY

Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers

(2012) Ramaswamy Govindan et al.   CELL

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

(2011) S.-R. Woo et al.   CANCER RESEARCH

Epidermal Growth Factor Receptor Inhibition Augments the Expression of MHC Class I and II Genes

(2011) B. P. Pollack et al.   CLINICAL CANCER RESEARCH

CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression

(2010) Xueqing Sun et al.   CANCER AND METASTASIS REVIEWS

Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib

(2010) Emma Guttman-Yassky et al.   EUROPEAN JOURNAL OF CANCER

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

(2010) Kaori Sakuishi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Keratinocyte-Associated B7-H1 Directly Regulates Cutaneous Effector CD8+ T Cell Responses

(2010) P. Ritprajak et al.   JOURNAL OF IMMUNOLOGY

Keratinocytes Function as Accessory Cells for Presentation of Endogenous Antigen Expressed in the Epidermis

(2009) Brian S. Kim et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

EGFR Regulates the Expression of Keratinocyte-Derived Granulocyte/Macrophage Colony-Stimulating Factor In Vitro and In Vivo

(2009) Francesca Mascia et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Skin toxicities associated with epidermal growth factor receptor inhibitors

(2009) Tianhong Li et al.   Targeted Oncology

The Epidermal Growth Factor Receptor System in Skin Repair and Inflammation

(2007) Saveria Pastore et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY